[
  {
    "ts": null,
    "headline": "Phase 3 results for Lilly's Jaypirca® (pirtobrutinib) in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual Meeting",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) previously treated with a covalent BTK inhibitor. The study's primary endpoint of progression-free survival (PFS) was met at primary analysis1, demonstrating pirtobrutinib was superior to investigator's choice of idela",
    "url": "https://finnhub.io/api/news?id=295e344270c3df031444a681e2c80c0cb05ed491b40d6250616fa234306fe5dc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733784300,
      "headline": "Phase 3 results for Lilly's Jaypirca® (pirtobrutinib) in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual Meeting",
      "id": 131899962,
      "image": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) previously treated with a covalent BTK inhibitor. The study's primary endpoint of progression-free survival (PFS) was met at primary analysis1, demonstrating pirtobrutinib was superior to investigator's choice of idela",
      "url": "https://finnhub.io/api/news?id=295e344270c3df031444a681e2c80c0cb05ed491b40d6250616fa234306fe5dc"
    }
  },
  {
    "ts": null,
    "headline": "Toll Brothers, Eli Lilly, Amazon & Intuit: After-Hours Movers",
    "summary": "Asking for a Trend's Josh Lipton checks out the top trending stocks in the after-hours trading session. Toll Brothers (TOL) stock slips despite topping fiscal fourth quarter estimates. Pharma giant Eli Lilly (LLY) announces a $15 billion share buyback program. Amazon (AMZN) is partnering with Intuit QuickBooks (INTU) to allow its third-party sellers access to their sales and inventory data on the program. To watch more expert insights and analysis on the latest market action, check out more Asking for a Trend here. This post was written by Luke Carberry Mogan.",
    "url": "https://finnhub.io/api/news?id=25603ca4c90828d68b0e21ebb3a5442e524150cb34be7694727ada6885bfa565",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733783395,
      "headline": "Toll Brothers, Eli Lilly, Amazon & Intuit: After-Hours Movers",
      "id": 131885955,
      "image": "https://s.yimg.com/ny/api/res/1.2/RhRa4WH6xAh8Pkg0cVNdIw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://s.yimg.com/os/creatr-uploaded-images/2024-12/18089e80-b67d-11ef-9a5f-1e607e82810b",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Asking for a Trend's Josh Lipton checks out the top trending stocks in the after-hours trading session. Toll Brothers (TOL) stock slips despite topping fiscal fourth quarter estimates. Pharma giant Eli Lilly (LLY) announces a $15 billion share buyback program. Amazon (AMZN) is partnering with Intuit QuickBooks (INTU) to allow its third-party sellers access to their sales and inventory data on the program. To watch more expert insights and analysis on the latest market action, check out more Asking for a Trend here. This post was written by Luke Carberry Mogan.",
      "url": "https://finnhub.io/api/news?id=25603ca4c90828d68b0e21ebb3a5442e524150cb34be7694727ada6885bfa565"
    }
  },
  {
    "ts": null,
    "headline": "Lilly Approves $15 Billion in Share Buybacks, Raises Dividend",
    "summary": "(Bloomberg) -- Eli Lilly & Co. approved a program to buy back as much as $15 billion of its own shares amid rapid growth fueled in part by the blockbuster weight-loss drug Zepbound.Most Read from BloombergBrace for a Nationwide Shuffle of Corporate HeadquartersA Chicago Skyscraper Cements the Legacy of a Visionary Postmodern ArchitectCloud Computing Tax Threatens Chicago’s Silicon Valley AmbitionsNYC’s Run-Down Bus Terminal Gets Approval for $10 Billion RevampKansas City Looks Back on its Long,",
    "url": "https://finnhub.io/api/news?id=38877ac616d0c5873d24d1a50da8871396e2bcde2700157dd2d5dd178db9b256",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733780780,
      "headline": "Lilly Approves $15 Billion in Share Buybacks, Raises Dividend",
      "id": 131899964,
      "image": "https://s.yimg.com/ny/api/res/1.2/zvGnVeyPmdAEvyzQdmWBjA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/bloomberg_markets_842/18f0ab9f3fbfbc6e2c3db9c35b9e552e",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- Eli Lilly & Co. approved a program to buy back as much as $15 billion of its own shares amid rapid growth fueled in part by the blockbuster weight-loss drug Zepbound.Most Read from BloombergBrace for a Nationwide Shuffle of Corporate HeadquartersA Chicago Skyscraper Cements the Legacy of a Visionary Postmodern ArchitectCloud Computing Tax Threatens Chicago’s Silicon Valley AmbitionsNYC’s Run-Down Bus Terminal Gets Approval for $10 Billion RevampKansas City Looks Back on its Long,",
      "url": "https://finnhub.io/api/news?id=38877ac616d0c5873d24d1a50da8871396e2bcde2700157dd2d5dd178db9b256"
    }
  },
  {
    "ts": null,
    "headline": "Lilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase",
    "summary": "Today, the board of directors of Eli Lilly and Company (NYSE: LLY) approved a new $15 billion share repurchase program. The company's prior $5 billion share repurchase program was completed in the fourth quarter of 2024.",
    "url": "https://finnhub.io/api/news?id=dbb498de55fa0413e59ad8508801c9c14efe0535f9c956f133bf289747bfed9b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733778960,
      "headline": "Lilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase",
      "id": 131899965,
      "image": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Today, the board of directors of Eli Lilly and Company (NYSE: LLY) approved a new $15 billion share repurchase program. The company's prior $5 billion share repurchase program was completed in the fourth quarter of 2024.",
      "url": "https://finnhub.io/api/news?id=dbb498de55fa0413e59ad8508801c9c14efe0535f9c956f133bf289747bfed9b"
    }
  },
  {
    "ts": null,
    "headline": "Top Stock Reports for Eli Lilly, AbbVie & Gilead Sciences",
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie Inc. (ABBV) and Gilead Sciences, Inc. (GILD), as well as two micro-cap stocks, Air T, Inc. (AIRT) and Fossil Group, Inc. (FOSL).",
    "url": "https://finnhub.io/api/news?id=09fff222caed8ca9822231b9c36870ad1aab37e77fe8976c65f39e541e4ab1c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733775300,
      "headline": "Top Stock Reports for Eli Lilly, AbbVie & Gilead Sciences",
      "id": 131879613,
      "image": "https://media.zenfs.com/en/zacks.com/00f1f0c06254fc058ca373b7d8f260e5",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie Inc. (ABBV) and Gilead Sciences, Inc. (GILD), as well as two micro-cap stocks, Air T, Inc. (AIRT) and Fossil Group, Inc. (FOSL).",
      "url": "https://finnhub.io/api/news?id=09fff222caed8ca9822231b9c36870ad1aab37e77fe8976c65f39e541e4ab1c4"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Just Got One Step Closer to Resolving Wegovy Supply Issue",
    "summary": "The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.",
    "url": "https://finnhub.io/api/news?id=2955cc0b9fdd1132ce4b5bc2d29f670f11fc87de1e244399eb3cb9c8c996a1b2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733766240,
      "headline": "Novo Nordisk Just Got One Step Closer to Resolving Wegovy Supply Issue",
      "id": 131872435,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.",
      "url": "https://finnhub.io/api/news?id=2955cc0b9fdd1132ce4b5bc2d29f670f11fc87de1e244399eb3cb9c8c996a1b2"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock underperforms Monday when compared to competitors",
    "summary": "Eli Lilly & Co. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=6fc4a2501c5198766578aacc94db749c9b5f81b7a42a877bf0de6038af3b20d4",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733761980,
      "headline": "Eli Lilly & Co. stock underperforms Monday when compared to competitors",
      "id": 131932782,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=6fc4a2501c5198766578aacc94db749c9b5f81b7a42a877bf0de6038af3b20d4"
    }
  },
  {
    "ts": null,
    "headline": "BioAge halts ongoing Phase II trial of obesity drug due to liver concerns",
    "summary": "In the trail, 11 participants in the azelaprag group exhibited transaminase elevations without significant symptoms.",
    "url": "https://finnhub.io/api/news?id=60b6acef07d8987437137d3cd4763c3c26c81984f023ecb748916dce4dcb6ce5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733754492,
      "headline": "BioAge halts ongoing Phase II trial of obesity drug due to liver concerns",
      "id": 131869753,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/22/2024/12/CTA-3-BioAge-Shutterstock_2460903177.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In the trail, 11 participants in the azelaprag group exhibited transaminase elevations without significant symptoms.",
      "url": "https://finnhub.io/api/news?id=60b6acef07d8987437137d3cd4763c3c26c81984f023ecb748916dce4dcb6ce5"
    }
  },
  {
    "ts": null,
    "headline": "CORE Kidney, Boehringer Ingelheim and Lilly Are Turning Up the Volume on Kidney Health at the 2025 Tournament of Roses® Parade",
    "summary": "CORE Kidney, a patient support and advocacy group that helps patients with kidney disease navigate their complex journey, today announced its collaboration with Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) at the 2025 Tournament of Roses® Parade. The partners have joined forces to share a powerful reminder for those at risk for kidney disease: It takes two tests – blood and urine – to ensure complete testing. Those at risk include people living with type 2 diabetes or high blood pr",
    "url": "https://finnhub.io/api/news?id=0499bfe26275ab98f106e9377a009a0967ea604f18265e2c5d09a6da3027b22e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733752800,
      "headline": "CORE Kidney, Boehringer Ingelheim and Lilly Are Turning Up the Volume on Kidney Health at the 2025 Tournament of Roses® Parade",
      "id": 131869754,
      "image": "https://media.zenfs.com/en/prnewswire.com/103e342fcbbbda3b53835f96428928a3",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "CORE Kidney, a patient support and advocacy group that helps patients with kidney disease navigate their complex journey, today announced its collaboration with Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) at the 2025 Tournament of Roses® Parade. The partners have joined forces to share a powerful reminder for those at risk for kidney disease: It takes two tests – blood and urine – to ensure complete testing. Those at risk include people living with type 2 diabetes or high blood pr",
      "url": "https://finnhub.io/api/news?id=0499bfe26275ab98f106e9377a009a0967ea604f18265e2c5d09a6da3027b22e"
    }
  },
  {
    "ts": null,
    "headline": "Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns",
    "summary": "On Friday, BioAge Labs Inc. (NASDAQ:BIOA) announced that it will discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate, azelaprag. STRIDES was being conducted in collaboration with Eli Lilly And Co’s (NYSE:LLY) Chorus clinical development organization. Top-line results were anticipated in the third quarter of 2025. The move follows after liver transaminitis without clinically significant symptoms was observed in some subjects receiving azelaprag. STRIDES is a Phase",
    "url": "https://finnhub.io/api/news?id=530ae400c11f9ddd16afe9e4771d583bc7c0b10c09f2044137e006a981acc19d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733748082,
      "headline": "Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns",
      "id": 131869757,
      "image": "https://media.zenfs.com/en/Benzinga/a2caea8ec66bfba10e247cae98d4bd2e",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "On Friday, BioAge Labs Inc. (NASDAQ:BIOA) announced that it will discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate, azelaprag. STRIDES was being conducted in collaboration with Eli Lilly And Co’s (NYSE:LLY) Chorus clinical development organization. Top-line results were anticipated in the third quarter of 2025. The move follows after liver transaminitis without clinically significant symptoms was observed in some subjects receiving azelaprag. STRIDES is a Phase",
      "url": "https://finnhub.io/api/news?id=530ae400c11f9ddd16afe9e4771d583bc7c0b10c09f2044137e006a981acc19d"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Just Got Even Sweeter. Here's Why It's Worth Buying Now",
    "summary": "According to a sneak peek of the data from one of Eli Lilly's (NYSE: LLY) late-stage clinical trials, the cardiometabolic medicine juggernaut now looks even stronger in comparison to its similarly powerful arch-rival, Novo Nordisk, (NYSE: NVO) and it isn't the first time.  One of the most important questions about the competitive prospects of Lilly against Novo Nordisk in the market for anti-obesity medicines is, quite simply, which company makes the more effective drug.  While it's typically beneficial to have more than one intervention to choose from, it's also obvious that, on average, physicians will first reach for the tool that's proven to be better, which directly impacts a drug's market share.",
    "url": "https://finnhub.io/api/news?id=60682b37a4490d9868655b6fbe25e5a6cc425f458a19f9ef79819bc2f356c3fc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733738340,
      "headline": "Eli Lilly Stock Just Got Even Sweeter. Here's Why It's Worth Buying Now",
      "id": 131867970,
      "image": "https://g.foolcdn.com/editorial/images/800087/two-pharmacists-chat-in-the-pharmacy.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "According to a sneak peek of the data from one of Eli Lilly's (NYSE: LLY) late-stage clinical trials, the cardiometabolic medicine juggernaut now looks even stronger in comparison to its similarly powerful arch-rival, Novo Nordisk, (NYSE: NVO) and it isn't the first time.  One of the most important questions about the competitive prospects of Lilly against Novo Nordisk in the market for anti-obesity medicines is, quite simply, which company makes the more effective drug.  While it's typically beneficial to have more than one intervention to choose from, it's also obvious that, on average, physicians will first reach for the tool that's proven to be better, which directly impacts a drug's market share.",
      "url": "https://finnhub.io/api/news?id=60682b37a4490d9868655b6fbe25e5a6cc425f458a19f9ef79819bc2f356c3fc"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Eli Lilly, Novo Nordisk's  Amgen and Viking Therapeutics",
    "summary": "Eli Lilly, Novo Nordisk's Amgen and Viking Therapeutics are included in this Analyst Blog.",
    "url": "https://finnhub.io/api/news?id=423ce408badc38de851bc3fce6f8b77f20f5882cc5af1ff7b42397e67687a4dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733727060,
      "headline": "The Zacks Analyst Blog Eli Lilly, Novo Nordisk's  Amgen and Viking Therapeutics",
      "id": 131867971,
      "image": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly, Novo Nordisk's Amgen and Viking Therapeutics are included in this Analyst Blog.",
      "url": "https://finnhub.io/api/news?id=423ce408badc38de851bc3fce6f8b77f20f5882cc5af1ff7b42397e67687a4dd"
    }
  },
  {
    "ts": null,
    "headline": "Apple Tops the List of Best-Managed Companies of 2024",
    "summary": "Tech companies hold six of the top 10 spots, while Mastercard jumped to fifth place from 24th last year.",
    "url": "https://finnhub.io/api/news?id=d13cca814be7a6fe4ddcc7139ff6790f37d3900f98cf04b25ea44b1a3c44b23e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733710440,
      "headline": "Apple Tops the List of Best-Managed Companies of 2024",
      "id": 131864915,
      "image": "https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Tech companies hold six of the top 10 spots, while Mastercard jumped to fifth place from 24th last year.",
      "url": "https://finnhub.io/api/news?id=d13cca814be7a6fe4ddcc7139ff6790f37d3900f98cf04b25ea44b1a3c44b23e"
    }
  }
]